Outcome of Board for approval of Audited Financial Results for Financial Year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved audited financial results for FY ended March 31, 2025. On a standalone basis, total income fell sharply to Rs. 215.56 lakhs from Rs. 501.34 lakhs in FY24, a drop of about 57%, mainly because the prior year included a one-time Rs. 498 lakhs sale line. Despite the revenue dip, the company swung to a standalone profit after tax of Rs. 73.19 lakhs versus Rs. 44.79 lakhs last year, driven by other income and a deferred tax credit. EPS stood at Rs. 0.18 (standalone) and Rs. 0.05 (consolidated). On the consolidated side, the statutory auditors issued a qualified opinion, and both standalone and consolidated results flag a going concern note because current liabilities exceed current assets (by Rs. 3,686.48 lakhs standalone and Rs. 686.8 lakhs consolidated). Management says the gap is covered by promoter/associate company support, BSE trading has been restored, and an MOU with Dismutase Biotech and planned M&A should revive the business. Operating cash flow was negative at Rs. (491) lakhs standalone and Rs. (593) lakhs consolidated. The Board also fixed the 33rd AGM for August 21, 2025, appointed Sridharan & Sridharan as Secretarial Auditors for 5 years, and re-appointed Mr. Narayanamurthi as Chairman & MD for another 5-year term.
Mixed for shareholders: standalone profit improved and promoter support is reassuring, but a 57% revenue slump, a qualified auditor opinion on consolidated numbers, an explicit going concern flag, and large negative operating cash flows are red flags that may keep the stock volatile and risky for short-term investors.